What tests should be used to evaluate a woman for possible ovarian cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testing to Predict Ovarian Cancer

When evaluating a woman for possible ovarian cancer, perform serum CA-125 measurement combined with expert transvaginal and transabdominal ultrasound, followed by CT imaging of the thorax, abdomen, and pelvis for staging and surgical planning. 1

Initial Diagnostic Workup

The standard evaluation for suspected ovarian cancer requires a systematic approach:

  • Serum CA-125 testing is the primary tumor marker and is elevated in approximately 85% of patients with advanced disease, though only 50% of FIGO stage I cases 1
  • Expert ultrasound examination (both transabdominal and transvaginal) is the recommended first-line imaging modality 1
  • CT scanning of thorax, abdomen, and pelvis should be performed to complete clinical staging and aid surgical planning 1

Ultrasound-Based Risk Models

US-based diagnostic models (IOTA Simple Rules or IOTA ADNEX model) are superior to CA-125 alone, HE4, or the Risk of Ovarian Malignancy Algorithm for distinguishing benign from malignant ovarian tumors. 1 These models outperformed the Risk of Malignancy Index in randomized controlled trials.

Additional Tumor Markers for Specific Scenarios

Mucinous Carcinoma Evaluation

  • Measure serum CEA and CA 19-9 in addition to CA-125 when mucinous carcinoma is suspected to help distinguish primary ovarian tumors from gastrointestinal metastases 1
  • Consider endoscopy if CA-125/CEA ratio is <25:1, as this suggests possible gastrointestinal origin 1

Pregnancy-Related Considerations

  • Routine measurement of beta-hCG and alpha-fetoprotein is NOT recommended during pregnancy for ovarian mass evaluation 1
  • MRI is recommended as a second-stage test for characterizing indeterminate ovarian masses in pregnant women 1

Pathological Confirmation Requirements

Definitive diagnosis requires pathological examination by an expert pathologist of tumor samples from either diagnostic biopsy or surgical specimen. 1 Adequate tissue is essential, particularly if neoadjuvant chemotherapy is planned, to allow genetic tumor testing for therapeutic stratification.

Essential Immunohistochemistry Panel

For diagnostic biopsies with morphological suspicion of low-grade or high-grade serous carcinoma, perform at minimum: PAX8, estrogen receptor, WT-1, and p53 immunohistochemistry. 1

Additional Molecular Testing

  • DNA mismatch repair IHC and/or microsatellite instability testing is mandatory in ovarian endometrioid carcinoma and clear-cell carcinoma to identify Lynch syndrome-related cases 1
  • HER2 testing can be considered in mucinous carcinoma to identify patients for HER2-targeted strategies 1
  • KRAS and BRAF mutational testing can be considered in low-grade serous carcinoma for targeted therapy identification 1

Important Caveats

CA-125 has significant limitations: It is not specific to ovarian cancer and may be elevated in non-gynecological malignancies and benign conditions including endometriosis and ovarian cysts. 1 This is why combining CA-125 with expert ultrasound interpretation is critical.

Screening is NOT recommended: Despite these diagnostic tools, guidelines recommend against routine screening for ovarian cancer in average-risk women because screening is ineffective and associated with harm. 2 These tests are for diagnostic evaluation of symptomatic women or those with suspicious findings, not for screening asymptomatic populations.

Cytological assessment of pleural effusion should be performed if present during initial workup. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Research

Diagnosis and Management of Ovarian Cancer.

American family physician, 2016

Related Questions

What preoperative assessment and peri‑operative management should be provided for patients undergoing total abdominal hysterectomy with bilateral salpingo‑oophorectomy for ovarian cancer?
What is the recommended screening protocol for ovarian cancer in symptomatic individuals?
What is the workup for ovarian cancer?
In a 46-year-old woman with chronic neck and back pain who now has a six-week history of bilateral hand numbness and full range of motion, what are the appropriate next diagnostic tests?
What is the most appropriate next step in managing a 55-year-old postmenopausal woman with a family history of ovarian cancer and no known genetic testing?
What are the risks and recommended management if a patient in early pregnancy inadvertently takes a tablet of norethisterone (synthetic progestogen)?
What is the best antibiotic for a catheterized adult woman with purple‑urine bag syndrome and a suspected urinary tract infection?
What is the prognosis for a 61‑year‑old man with intermediate‑risk chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL‑IPI score 3, IGHV unmutated, Rai stage I) after palliative radiation and four cycles of obinutuzumab (Gazyva) with a starter pack of venetoclax (Venclexta), now experiencing significant functional decline and unable to tolerate further therapy?
How should high platelet count (thrombocytosis) be evaluated and managed in a pediatric patient?
Can topical diclofenac gel be used concurrently with oral meloxicam?
What is the ICD‑10‑CM code for an inferior‑posterior nondisplaced L1 vertebral end‑plate fracture?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question